Humanized mice as a model for aberrant responses in human T cell immunotherapy

Journal of Immunology

Volumn 193, Issue 2, 2014, Pages 587-596

  Vudattu, Nalini K ^a   Waldron Lynch, Frank ^a   Truman, Lucy A ^a   Deng, Songyan ^a   Preston Hurlburt, Paula ^a   Torres, Richard ^a   Raycroft, Maurice T ^a   Mamula, Mark J ^a   Herold, Kevan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; IPILIMUMAB; STAT5 PROTEIN; TEPLIZUMAB; TUMOR NECROSIS FACTOR;

ADRENAL DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE ADRENALITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE SIALITIS; AUTOIMMUNITY; CD25+ CD127- REGULATORY T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MACROPHAGE MIGRATION; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WEIGHT REDUCTION;

ADRENAL GLANDS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LIVER; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; PHOSPHORYLATION; STAT5 TRANSCRIPTION FACTOR; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HETEROLOGOUS; WEIGHT LOSS;

EID: 84904251418     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302455     Document Type: Article

References (56)

1. Seok, J., H. S. Warren, A. G. Cuenca, M. N. Mindrinos, H. V. Baker, W. Xu, D. R. Richards, G. P. McDonald-Smith, H. Gao, L. Hennessy, et al; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. 2013. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. USA 110: 3507-3512.
2. Mestas, J., and C. C. Hughes. 2004. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172: 2731-2738.
3. Unger, W. W., T. Pearson, J. R. Abreu, S. Laban, A. R. van der Slik, S. M. der Kracht, M. G. Kester, D. V. Serreze, L. D. Shultz, M. Griffioen, et al. 2012. Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice. PLoS ONE 7: e49213.
4. Kuhn, C., S. You, F. Valette, G. Hale, P. van Endert, J. F. Bach, H. Waldmann, and L. Chatenoud. 2011. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci. Transl. Med. 3: 68ra10.
5. Rathinam, C., W. T. Poueymirou, J. Rojas, A. J. Murphy, D. M. Valenzuela, G. D. Yancopoulos, A. Rongvaux, E. E. Eynon, M. G. Manz, and R. A. Flavell. 2011. Efficient differentiation and function of human macrophages in humanized CSF-1 mice. Blood 118: 3119-3128.
6. Banuelos, S. J., L. D. Shultz, D. L. Greiner, L. M. Burzenski, B. Gott, B. L. Lyons, A. A. Rossini, and M. C. Appel. 2004. Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice. Clin. Immunol. 112: 273-283.
7. Libby, S. J., M. A. Brehm, D. L. Greiner, L. D. Shultz, M. McClelland, K. D. Smith, B. T. Cookson, J. E. Karlinsey, T. L. Kinkel, S. Porwollik, et al. 2010. Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection. Proc. Natl. Acad. Sci. USA 107: 15589-15594.
8. Shultz, L. D., F. Ishikawa, and D. L. Greiner. 2007. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7: 118-130.
9. Shultz, L. D., T. Pearson, M. King, L. Giassi, L. Carney, B. Gott, B. Lyons, A. A. Rossini, and D. L. Greiner. 2007. Humanized NOD/LtSz-scid IL2 receptor common gamma chain knockout mice in diabetes research. Ann. N. Y. Acad. Sci. 1103: 77-89.
10. Linsley, P. S.,W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174: 561-569.
11. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405-413.
12. Brunet, J. F., F. Denizot, M. F. Luciani, M. Roux-Dosseto, M. Suzan, M. G. Mattei, and P. Golstein. 1987. A new member of the immunoglobulin superfamily - CTLA-4. Nature 328: 267-270.
13. Walunas, T. L., C. Y. Bakker, and J. A. Bluestone. 1996. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183: 2541-2550.
14. van der Merwe, P. A., D. L. Bodian, S. Daenke, P. Linsley, and S. J. Davis. 1997. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J. Exp. Med. 185: 393-403.
15. Ostrov, D. A., W. Shi, J. C. Schwartz, S. C. Almo, and S. G. Nathenson. 2000. Structure of murine CTLA-4 and its role in modulating T cell responsiveness. Science 290: 816-819.
16. Marengère, L. E., P. Waterhouse, G. S. Duncan, H. W. Mittrücker, G. S. Feng, and T. W. Mak. 1996. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 272: 1170-1173.
17. Chuang, E., T. S. Fisher, R. W. Morgan, M. D. Robbins, J. M. Duerr, M. G. Vander Heiden, J. P. Gardner, J. E. Hambor, M. J. Neveu, and C. B. Thompson. 2000. The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity 13: 313-322.
18. Lee, K. M., E. Chuang, M. Griffin, R. Khattri, D. K. Hong, W. Zhang, D. Straus, L. E. Samelson, C. B. Thompson, and J. A. Bluestone. 1998. Molecular basis of T cell inactivation by CTLA-4. Science 282: 2263-2266.
19. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.
20. Chambers, C. A., T. J. Sullivan, and J. P. Allison. 1997. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation- dependent activation of CD4+ T cells. Immunity 7: 885-895.
21. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
22. Takahashi, T., T. Tagami, S. Yamazaki, T. Uede, J. Shimizu, N. Sakaguchi, T. W. Mak, and S. Sakaguchi. 2000. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192: 303-310.
23. Brunner, M. C., C. A. Chambers, F. K. Chan, J. Hanke, A. Winoto, and J. P. Allison. 1999. CTLA-4-mediated inhibition of early events of T cell proliferation. J. Immunol. 162: 5813-5820.
24. Jain, N., H. Nguyen, C. Chambers, and J. Kang. 2010. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc. Natl. Acad. Sci. USA 107: 1524-1528.
25. Yamaguchi, T., A. Kishi, M. Osaki, H. Morikawa, P. Prieto-Martin, K. Wing, T. Saito, and S. Sakaguchi. 2013. Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression. Proc. Natl. Acad. Sci. USA 110: E2116-E2125.
26. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377.
27. Quezada, S. A., K. S. Peggs, M. A. Curran, and J. P. Allison. 2006. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116: 1935-1945.
28. Kaehler, K. C., S. Piel, E. Livingstone, B. Schilling, A. Hauschild, and D. Schadendorf. 2010. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin. Oncol. 37: 485-498.
29. Zielinski, C. E., S. N. Jacob, F. Bouzahzah, B. E. Ehrlich, and J. Craft. 2005. Naive CD4+ T cells from lupus-prone Fas-intact MRL mice display TCR-mediated hyperproliferation due to intrinsic threshold defects in activation. J. Immunol. 174: 5100-5109.
30. Herold, K. C., S. E. Gitelman, M. R. Ehlers, P. A. Gottlieb, C. J. Greenbaum, W. Hagopian, K. D. Boyle, L. Keyes-Elstein, S. Aggarwal, D. Phippard, et al; AbATE Study Team. 2013. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62: 3766-3774.
31. Herold, K. C., S. E. Gitelman, U. Masharani, W. Hagopian, B. Bisikirska, D. Donaldson, K. Rother, B. Diamond, D. M. Harlan, and J. A. Bluestone. 2005. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54: 1763-1769.
32. Herold, K. C., S. E. Gitelman, S. M. Willi, P. A. Gottlieb, F. Waldron-Lynch, L. Devine, J. Sherr, S. M. Rosenthal, S. Adi, M. Y. Jalaludin, et al. 2013. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 56: 391-400.
33. Herold, K. C., W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, and J. A. Bluestone. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346: 1692-1698.
34. Sherry, N., W. Hagopian, J. Ludvigsson, S. M. Jain, J. Wahlen, R. J. Ferry, Jr., B. Bode, S. Aronoff, C. Holland, D. Carlin, et al. 2011. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet. 378: 487-497.
35. Weber, J. S., S. O'Day, W. Urba, J. Powderly, G. Nichol, M. Yellin, J. Snively, and E. Hersh. 2008. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26: 5950-5956.
36. Waldron-Lynch, F., O. Henegariu, S. Deng, P. Preston-Hurlburt, J. Tooley, R. Flavell, and K. C. Herold. 2012. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci. Transl. Med. 4: 118ra112.
37. Vudattu, N. K., I. Magalhaes, M. Schmidt, V. Seyfert-Margolis, and M. J. Maeurer. 2007. Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer. Int. J. Cancer 121: 1512-1519.
38. Della Vittoria Scarpati, G., C. Fusciello, F. Perri, F. Sabbatino, S. Ferrone, C. Carlomagno, and S. Pepe. 2014. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco. Targets Ther. 7: 203-209.
39. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.
40. Min, L., and N. Ibrahim. 2013. Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol. 1: e15.
41. Dillard, T., C. G. Yedinak, J. Alumkal, and M. Fleseriu. 2010. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13: 29-38.
42. Antonelli, A., S. M. Ferrari, D. Giuggioli, E. Ferrannini, C. Ferri, and P. Fallahi. 2014. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimm. Rev. 13: 272-280.
43. Pino, S., M. A. Brehm, L. Covassin-Barberis, M. King, B. Gott, T. H. Chase, J. Wagner, L. Burzenski, O. Foreman, D. L. Greiner, and L. D. Shultz. 2010. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease. Methods Mol. Biol. 602: 105-117.
44. Zhu, J., X. Liu, C. Xie, M. Yan, Y. Yu, E. S. Sobel, E. K. Wakeland, and C. Mohan. 2005. T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J. Clin. Invest. 115: 1869-1878.
45. Hansen, A., P. E. Lipsky, and T. Dörner. 2007. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat. Clin. Pract. Rheumatol. 3: 561-569.
46. Khattri, R., J. A. Auger, M. D. Griffin, A. H. Sharpe, and J. A. Bluestone. 1999. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J. Immunol. 162: 5784-5791.
47. Zheng, J., Y. Liu, Y. Liu, M. Liu, Z. Xiang, K. T. Lam, D. B. Lewis, Y. L. Lau, and W. Tu. 2013. Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice. Sci. Transl. Med. 5: 168ra9.
48. Verhagen, J., R. Genolet, G. J. Britton, B. J. Stevenson, C. A. Sabatos-Peyton, J. Dyson, I. F. Luescher, and D. C. Wraith. 2013. CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire. Proc. Natl. Acad. Sci. USA 110: E221-E230.
49. Mirenda, V., S. J. Jarmin, R. David, J. Dyson, D. Scott, Y. Gu, R. I. Lechler, K. Okkenhaug, and F. M. Marelli-Berg. 2007. Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood 109: 2968-2977.
50. Nie, H., Y. Zheng, R. Li, T. B. Guo, D. He, L. Fang, X. Liu, L. Xiao, X. Chen, B. Wan, et al. 2013. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat. Med. 19:322-328.
51. Vudattu, N. K., K. Strle, A. C. Steere, and E. E. Drouin. 2013. Dysregulation of CD4+CD25(high) T cells in the synovial fluid of patients with antibiotic-refractory Lyme arthritis. Arthritis Rheum. 65: 1643-1653.
52. Ablamunits, V., O. Henegariu, P. Preston-Hurlburt, and K. C. Herold. 2011. NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody. Eur. J. Immunol. 41: 1832-1842.
53. Belghith, M., J. A. Bluestone, S. Barriot, J. Mégret, J. F. Bach, and L. Chatenoud. 2003. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9: 1202-1208.
54. Bisikirska, B., J. Colgan, J. Luban, J. A. Bluestone, and K. C. Herold. 2005. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J. Clin. Invest. 115: 2904-2913.
55. Rongvaux, A., T. Willinger, J. Martinek, T. Strowig, S. V. Gearty, L. L. Teichmann, Y. Saito, F. Marches, S. Halene, A. K. Palucka, et al. 2014. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32: 364-372.
56. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the non-obese diabetic mouse. J. Exp. Med. 181: 1145-1155.